ASCO: J&J, Legend reveal more CAR-T data and a look at Carvykti for earlier myeloma in a difficult population

Legend Biotech and partner Johnson & Johnson just keep rolling out new data on Carvykti. The latest? The closely watched CAR-T therapy sustained an effect in heavily pretreated multiple myeloma patients and shrank tumors when given earlier in a population with otherwise unyielding disease.